Rather than a one-size-fits-all blood test that looks for a single pathology, NeuroDex is commercializing a novel scientific approach, based on the study of extracellular vesicles – that can decipher “mixed pathology” in dementia and lead to a more personalized treatment plan. The Challenge Whenever we write about a company in the Alzheimer’s Moonshot we…
Press Release NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research Natick, Massachusetts (November 6, 2024) – NeuroDex Inc. (“NeuroDex” or the “Company”) proudly announces its selection as a recipient of the Target ALS Biomarker Consortia Grant. This significant funding will bolster NeuroDex’s efforts to pioneer novel blood-based biomarkers, aiming to…
We are thrilled to announce that Dr. Erez Eitan, NeuroDex’s chief scientific officer (CSO), will participate in the upcoming Alzheimer’s Association International Conference (AAIC) 2024. This prestigious event, taking place from July 28 to August 1 in Philadelphia, USA, will bring together leading scientists, researchers, and healthcare professionals from around the globe to discuss the…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
NATICK, MA, USA, October 31, 2023 /EINPresswire.com/ — NeuroDex, Inc. (“NeuroDex”, or the “Company”), announces that it has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study “Neuronal extracellular vesicles blood-based biomarker for lysosomal function.” This award will enable NeuroDex to utilize its unique ExoSORT™ platform to develop an…
Introduction: Neurodex is pleased to announce its participation in the upcoming 2nd Annual Meeting hosted by the American Association of Extracellular Vesicles (AAEV). Set against the picturesque backdrop of Boston, MA, this event promises to gather esteemed experts in extracellular vesicle research. Neurodex is gearing up to share its latest insights into the study of…
We are delighted to announce that Dr. Erez Eitan, Chief Scientific Officer of NeuroDex, will speak at the upcoming International Society for Extracellular Vesicles (ISEV) Workshop titled “EV-based Biomarkers: Commercialization and Clinical Implementation.” Scheduled to take place in the picturesque city of Aalborg, Denmark, from October 12th to 14th, 2023, this workshop is set to…
Introduction: Parkinson’s disease is a progressive neurological disorder affecting millions worldwide. It is characterized by tremors, stiffness, and impaired movement, among other symptoms. Despite decades of research, there is currently no cure for Parkinson’s disease, and limited treatment options are available to patients. However, recent advances in biomarker research offer hope for earlier detection and…
NATICK, MASSACHUSETTS, UNITED STATES OF AMERICA, March 28, 2023/EINPresswire.com/ — NeuroDex, Inc.’s approved application, titled “Clinical Validation of a Robust Blood Test Using Neuron-Derived Exosomes for Detection of Alpha-Synuclein/TDP43 Pathologies in Patients with Alzheimer’s Disease,” highlights NeuroDex, Inc.’s unique methodology for isolation and analysis of neuron-derived exosomes.NeuroDex, Inc. (“NeuroDex”, or the “Company”), announces that it has…
Neurodegenerative diseases Neurodegenerative diseases are a complex and growing public health concern. These conditions, including Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia, can cause significant disability and reduced quality of life. Unfortunately, diagnosing these diseases can be challenging, with current diagnostic methods often requiring invasive procedures, such as brain imaging or lumbar puncture. Neurodex…